Tonix Pharmaceuticals to Acquire Zembrace SymTouch and Tosymra from Upsher-Smith Laboratories for Acute Migraine
Shots:
- Upsher-Smith to receive $12M up front & an additional $3M in Mar 2024, or earlier at the conclusion of the transition services period, and $10M to acquire product-related inventories. The transaction is expected to close on June 30, 2023
- Zembrace SymTouch & Tosymra are indicated for acute migraine with/out aura in adults & currently have patent protection to 2036 & 2031, respectively. Zembrace SymTouch showed migraine pain freedom for 46% vs 27% of patients at 2hrs. in a single-attack, double-blind study
- For ~9mos., Upsher-Smith will assist Tonix with transitioning the products by offering a few commercial operations, regulatory & other services. The acquisition also strengthens Tonix’s commercial capabilities & infrastructure for a potential launch of TNX-102 SL for fibromyalgia
Ref: Globenewswire | Image: Tonix
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
